电磁引导多叶准直器跟踪放疗用于前列腺癌的前瞻性临床试验结果
主要终点可行性达到(全部858个分次成功 delivery,P < .001),MLC跟踪将束靶几何对准的均方根误差从1.4 mm改善至0.90 mm,并改善前列腺剂量覆盖、减少危机器官每日剂量变异,未观察到急性≥3级泌尿生殖或胃肠道毒性。
要点
- 电磁引导MLC跟踪前列腺癌放疗可行,858个计划分次全部成功 delivery(P < .001)。
- MLC跟踪将束靶几何对准均方根误差从1.4 mm降至0.90 mm。
- 未观察到急性≥3级泌尿生殖或胃肠道毒性。
核心结论
- 电磁引导MLC跟踪放疗用于前列腺癌是可行的。
- 患者获得了改善的几何靶向,且实际 delivery 的剂量分布比未使用电磁引导MLC跟踪时更接近计划。
- 未观察到显著急性毒性。
研究设计与样本
- 采用电磁引导MLC跟踪结合容积旋转调强放疗,共 delivery 858个分次,分次剂量2至13.75 Gy。
- 主要终点为可行性,成功标准为>95%分次成功 delivery;次要终点包括束靶几何对准改善、前列腺剂量覆盖与危机器官保护改善、无急性≥3级泌尿生殖或胃肠道毒性。
主要发现
- 全部858个计划分次均成功 delivery with MLC跟踪,达到主要终点可行性(P < .001)。
- MLC跟踪将束靶几何对准的均方根误差从1.4 mm改善至0.90 mm。
- MLC跟踪改善了前列腺剂量覆盖并减少了危机器官每日剂量变异。
- 未观察到急性≥3级泌尿生殖或胃肠道毒性。
关键数值与推荐
- 可行性成功标准为>95%分次成功 delivery,实际858/858分次成功(P < .001)。
- 束靶几何对准均方根误差从1.4 mm改善至0.90 mm。
- 分次剂量范围为2至13.75 Gy。
临床怎么用
- 前列腺癌放疗可采用电磁引导MLC跟踪结合容积旋转调强放疗,以提高束靶几何对准和剂量分布准确性。
- 该技术在本试验中未增加急性≥3级泌尿生殖或胃肠道毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report on the primary and secondary outcomes of a prospective clinical trial of electromagnetic-guided multileaf collimator (MLC) tracking radiation therapy for prostate cancer. METHODS AND MATERIALS: Twenty-eight men with prostate cancer were treated with electromagnetic-guided MLC tracking with volumetric modulated arc therapy. A total of 858 fractions were delivered, with the dose per fraction ranging from 2 to 13.75 Gy. The primary outcome was feasibility, with success determined if >95% of fractions were successfully delivered. The secondary outcomes were (1) the improvement in beam-target geometric alignment, (2) the improvement in dosimetric coverage of the prostate and avoidance of critical structures, and (3) no acute grade ≥3 genitourinary or gastrointestinal toxicity. RESULTS: All 858 planned fractions were successfully delivered with MLC tracking, demonstrating the primary outcome of feasibility (P < .001). MLC tracking improved the beam-target geometric alignment from 1.4 to 0.90 mm (root-mean-square error). MLC tracking improved the dosimetric coverage of the prostate and reduced the daily variation in dose to critical structures. No acute grade ≥3 genitourinary or gastrointestinal toxicity was observed. CONCLUSIONS: Electromagnetic-guided MLC tracking radiation therapy for prostate cancer is feasible. The patients received improved geometric targeting and delivered dose distributions that were closer to those planned than they would have received without electromagnetic-guided MLC tracking. No significant acute toxicity was observed.
引用
- Keall PJ, Colvill E, O'Brien R, et al. Electromagnetic-Guided MLC Tracking Radiation Therapy for Prostate Cancer Patients: Prospective Clinical Trial Results. Int J Radiat Oncol Biol Phys. 2018. PMID: 29534898. doi:10.1016/j.ijrobp.2018.01.098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。